Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors or Progressive or Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors, With Emphasis on Non Small Cell Lung Cancer (NSCLC)
Status: Archived
University of California Davis Cancer Center
2042
mi
from 43215
Sacramento, CA
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors or Progressive or Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors, With Emphasis on Non Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
2042
mi
from 43215
Sacramento, CA
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Stanford University School of Medicine
2100
mi
from 43215
Stanford, CA
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Updated: 1/1/1970
Stanford University School of Medicine
2100
mi
from 43215
Stanford, CA
Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Phase I/II Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Phase I/II Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors
Status: Archived
Vanderbilt University Medical Center
2018
mi
from 43215
Ventura, CA
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
2018
mi
from 43215
Ventura, CA
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
University of Wisconsin-Madison, Department of Dermatology
393
mi
from 43215
Madison, WI
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison, Department of Dermatology
393
mi
from 43215
Madison, WI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Northwest Alabama Cancer Center, PC
439
mi
from 43215
Muscle Shoals, AL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Northwest Alabama Cancer Center, PC
439
mi
from 43215
Muscle Shoals, AL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Lancanster Cancer Center
354
mi
from 43215
Lancaster, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Lancanster Cancer Center
354
mi
from 43215
Lancaster, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
North Valley Hematology/Oncology Medical Group
1978
mi
from 43215
Mission Hills, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
North Valley Hematology/Oncology Medical Group
1978
mi
from 43215
Mission Hills, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Medical Oncology Care Associates
1959
mi
from 43215
Orange, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Medical Oncology Care Associates
1959
mi
from 43215
Orange, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Ajay Verma, MD
2059
mi
from 43215
Redding, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Ajay Verma, MD
2059
mi
from 43215
Redding, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Lee Cancer Clinic
928
mi
from 43215
Fort Myers, FL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Lee Cancer Clinic
928
mi
from 43215
Fort Myers, FL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Alexian Brothers Medical Center, 800 Biesterfield Rd.
295
mi
from 43215
Elk Grove Village, IL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Alexian Brothers Medical Center, 800 Biesterfield Rd.
295
mi
from 43215
Elk Grove Village, IL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Clarian Arnett Cancer Care
205
mi
from 43215
Lafayette, IN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clarian Arnett Cancer Care
205
mi
from 43215
Lafayette, IN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Medical Associates Clinic, PC
434
mi
from 43215
Dubuque, IA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Medical Associates Clinic, PC
434
mi
from 43215
Dubuque, IA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Kentucky Cancer Clinic
186
mi
from 43215
Hazard, KY
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Kentucky Cancer Clinic
186
mi
from 43215
Hazard, KY
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Kentuckiana Cancer Institute, PLLC
188
mi
from 43215
Louisville, KY
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Kentuckiana Cancer Institute, PLLC
188
mi
from 43215
Louisville, KY
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Medical Oncology LLC
801
mi
from 43215
Baton Rouge, LA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Medical Oncology LLC
801
mi
from 43215
Baton Rouge, LA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
West Michigan Regional Cancer & Blood Center
330
mi
from 43215
Freesoil, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
West Michigan Regional Cancer & Blood Center
330
mi
from 43215
Freesoil, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Community Cancer Care Specialists
181
mi
from 43215
Mount Clemens, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Community Cancer Care Specialists
181
mi
from 43215
Mount Clemens, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Huron Medical Center
210
mi
from 43215
Port Huron, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Huron Medical Center
210
mi
from 43215
Port Huron, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
St Louis Center for Clinical Studies
405
mi
from 43215
St Louis, MO
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
St Louis Center for Clinical Studies
405
mi
from 43215
St Louis, MO
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Nebraska Hematology-Oncology, PC
718
mi
from 43215
Lincoln, NE
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Nebraska Hematology-Oncology, PC
718
mi
from 43215
Lincoln, NE
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Southern Nevada Cancer Research Center
1757
mi
from 43215
Las Vegas, NV
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Southern Nevada Cancer Research Center
1757
mi
from 43215
Las Vegas, NV
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Summa Health System
110
mi
from 43215
Akron, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Summa Health System
110
mi
from 43215
Akron, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Hematology Associates
125
mi
from 43215
Bedford, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Hematology Associates
125
mi
from 43215
Bedford, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Oncology Hematology Care
86
mi
from 43215
Cincinnati, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Oncology Hematology Care
86
mi
from 43215
Cincinnati, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Signal Point Clinical Research Center, LLC
78
mi
from 43215
Middletown, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Signal Point Clinical Research Center, LLC
78
mi
from 43215
Middletown, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Gettysburg Cancer Center
307
mi
from 43215
Gettysburg, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Gettysburg Cancer Center
307
mi
from 43215
Gettysburg, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Penn State Milton S. Hershey Medical Center
337
mi
from 43215
Hershey, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Penn State Milton S. Hershey Medical Center
337
mi
from 43215
Hershey, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Landmark Medical Center
616
mi
from 43215
Woonsocket, RI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Landmark Medical Center
616
mi
from 43215
Woonsocket, RI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Cancer Center Associates of Carolina
447
mi
from 43215
Aiken, SC
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Cancer Center Associates of Carolina
447
mi
from 43215
Aiken, SC
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
McLeod Cancer & Blood Center
254
mi
from 43215
Johnson City, TN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
McLeod Cancer & Blood Center
254
mi
from 43215
Johnson City, TN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Tennessee Cancer Specialists
283
mi
from 43215
Knoxville, TN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Tennessee Cancer Specialists
283
mi
from 43215
Knoxville, TN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Lone Star Oncology - Austin
1059
mi
from 43215
Austin, TX
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Lone Star Oncology - Austin
1059
mi
from 43215
Austin, TX
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Hope Oncology
900
mi
from 43215
Richardson, TX
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Hope Oncology
900
mi
from 43215
Richardson, TX
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Masoom Kandahari, MD, PC
321
mi
from 43215
Woodbridge, VA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Masoom Kandahari, MD, PC
321
mi
from 43215
Woodbridge, VA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Olympic Hematology and Oncology
2020
mi
from 43215
Bremerton, WA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Olympic Hematology and Oncology
2020
mi
from 43215
Bremerton, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Arizona Cancer Center, University of Arizona
1639
mi
from 43215
Tucson, AZ
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Arizona Cancer Center, University of Arizona
1639
mi
from 43215
Tucson, AZ
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
USC Norris Comprehensive Cancer Center
1982
mi
from 43215
Los Angeles, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
1982
mi
from 43215
Los Angeles, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
2036
mi
from 43215
Marysville, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
2036
mi
from 43215
Marysville, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Chao Family Comprehensive Cancer Center
1959
mi
from 43215
Orange, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Chao Family Comprehensive Cancer Center
1959
mi
from 43215
Orange, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Valley Medical Oncology Consultants - Pleasanton
2081
mi
from 43215
Pleasanton, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Valley Medical Oncology Consultants - Pleasanton
2081
mi
from 43215
Pleasanton, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
University of California Davis Cancer Center
2042
mi
from 43215
Sacramento, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
2042
mi
from 43215
Sacramento, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
University of Colorado, Boulder
1179
mi
from 43215
Boulder, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
1179
mi
from 43215
Boulder, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Shaw Regional Cancer Center
1248
mi
from 43215
Edwards, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Shaw Regional Cancer Center
1248
mi
from 43215
Edwards, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Valley View Hospital Cancer Center
1287
mi
from 43215
Glenwood Springs, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Valley View Hospital Cancer Center
1287
mi
from 43215
Glenwood Springs, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Montrose Memorial Hospital Cancer Center
1329
mi
from 43215
Montrose, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Montrose Memorial Hospital Cancer Center
1329
mi
from 43215
Montrose, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
554
mi
from 43215
Hartford, CT
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
554
mi
from 43215
Hartford, CT